Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Pediatric Nephrology
Published in: Pediatric Nephrology 1/2013

01-01-2013 | Original Article

Outcome of severe steroid-dependent nephrotic syndrome treated with mycophenolate mofetil

Authors: Sushmita Banerjee, Amitava Pahari, Jayati Sengupta, Saroj K. Patnaik

Published in: Pediatric Nephrology | Issue 1/2013

Login to get access

Abstract

Background

Mycophenolate mofetil (MMF) is used as a steroid-sparing agent in pediatric nephrotic syndrome (NS). However, data about its long-term efficacy and safety is limited.

Methods

We report the long-term outcome of MMF therapy in 46 NS patients who remained steroid dependent (SD) despite previous treatment with levamisole and cyclophosphamide.

Results

After 1 year of MMF initiation, 32 (70 %) patients had reduced steroid requirement: 12 with decreased threshold dose and 20 were able to stop steroids. At follow-up of mean 3.56 (standard deviation + 1.76) years, 25 (54 %) children required no further alternative immunosuppression (IS), having infrequent or no relapses, of which 14 stopped MMF after a mean 2.4 (standard deviation + 0.9) years; 11 are continuing on MMF for a median of 2.25 years (range 1.33–7.75 years). One patient had a psoriasis flare, and MMF was stopped. No other patient required permanent drug withdrawal due to side effects. The outcome of patients who did not require further alternate IS was significantly better than those who did, with 56 % vs. 10.5 %, respectively, being off regular medications at last follow-up.

Conclusions

We conclude that MMF therapy is safe in the long term and allows >50 % of severe SDNS patients to avoid further toxic IS.
Literature
1.
Tarshish P, Tobin JN, Bernstein J, Edelman CM (1997) Prognostic significance of the early course of minimal change nephritic syndrome: report of the International Study of Kidney Disease in Children. J Am Soc Nephrol 8:769–776PubMed
2.
Niaudet P (2009) Long-term outcome of children with steroid sensitive idiopathic nephrotic syndrome. Clin J Am Soc Nephrol 4:1547–1548PubMedCrossRef
3.
Niaudet P, Boyer O (2009) Idiopathic nephrotic syndrome in children: clinical aspects. In: Pediatric Nephrology, 6th edition, editors: Avner ED, Harmon W, Naiudet P, Yoshikawa N. publishers: Springer-Verlag. 28:667–702
4.
Bagga A, Ali U, Banerjee S, Kanitkar M, Phadke KD, Senguttuvan P, Sethi S, Shah M, Indian Pediatric Nephrology Group, Indian Academy of Pediatrics (2008) Management of steroid sensitive nephrotic syndrome: revised guidelines. Indian Pediatr 45(3):203–214PubMed
5.
van Husen M, Kemper MJ (2011) New therapies in steroid-sensitive and steroid-resistant idiopathic nephrotic syndrome. Pediatr Nephrol 26(6):881–892PubMedCrossRef
6.
Hodson EM, Craig JC, Willis NS (2005) Evidence-based management of steroid-sensitive nephrotic syndrome. Pediatr Nephrol 20(11):1523–1530PubMedCrossRef
7.
Hodson EM, Alexander SI (2008) Evaluation and management of steroid-sensitive nephrotic syndrome. Curr Opin Pediatr 20(2):145–150PubMedCrossRef
8.
Dorresteijn EM, Kist-van Holthe JE, Levtchenko EN, Nauta J, Hop WC, van der Heijden AJ (2008) Mycophenolate mofetil versus cyclosporine for remission maintenance in nephrotic syndrome. Pediatr Nephrol 23(11):2013–2020PubMedCrossRef
9.
Al-Akash S, Al-Makdama A (2005) Mycophenolate mofetil in children with steroid-dependent and/or frequently relapsing nephrotic syndrome. Ann Saudi Med 25(5):380–384PubMed
10.
Hogg RJ, Fitzgibbons L, Bruick J, Bunke M, Ault B, Baqi N, Trachtman H, Swinford R (2006) Mycophenolate mofetil in children with frequently relapsing nephrotic syndrome: a report from the Southwest Pediatric Nephrology Study Group. Clin J Am Soc Nephrol 1(6):1173–1178PubMedCrossRef
11.
Novak I, Frank R, Vento S, Vergara M, Gauthier B, Trachtman H (2005) Efficacy of mycophenolate mofetil in pediatric patients with steroid-dependent nephrotic syndrome. Pediatr Nephrol 20(9):1265–1268PubMedCrossRef
12.
Baudouin V, Alberti C, Lapeyraque AL, Bensman A, André JL, Broux F, Cailliez M, Decramer S, Niaudet P, Deschênes G, Jacqz-Aigrain E, Loirat C (2012) Mycophenolate mofetil for steroid-dependent nephrotic syndrome: a phase II Bayesian trial. Pediatr Nephrol 27(3):389–396PubMedCrossRef
13.
Gipson DS, Massengill SF, Yao L, Nagaraj S, Smoyer WE, Mahan JD, Wigfall D, Miles P, Powell L, Lin JJ, Trachtman H, Greenbaum LA (2009) Management of childhood onset nephrotic syndrome. Pediatrics 124(2):747–757PubMedCrossRef
14.
Fujinaga S, Ohtomo Y, Hirano D, Nishizaki N, Someya T, Ohtsuka Y, Kaneko K, Shimizu T (2009) Mycophenolate mofetil therapy for childhood-onset steroid dependent nephrotic syndrome after long-term cyclosporine: extended experience in a single center. Clin Nephrol 72(4):268–273PubMed
15.
Barletta GM, Smoyer WE, Bunchman TE, Flynn JT, Kershaw DB (2009) Use of mycophenolate mofetil in steroid-dependent and resistant nephrotic syndrome. Pediatr Nephrol 18(8):833–837
16.
Mendizábal S, Zamora I, Berbel O, Sanahuja MJ, Fuentes J, Simon J (2005) Mycophenolate mofetil in steroid/cyclosporine-dependent/resistant nephritic syndrome. Pediatr Nephrol 20(7):914–919PubMedCrossRef
17.
Gellermann J, Querfeld U (2004) Frequently relapsing nephrotic syndrome: treatment with mycophenolate mofetil. Pediatr Nephrol 19(1):101–104PubMedCrossRef
18.
Afzal K, Bagga A, Menon S, Hari P, Jordan SC (2007) Treatment with Mycophenolate mofetil and prednisolone for steroid-dependent nephrotic syndrome. Pediatr Nephrol 22(12):2059–2065PubMedCrossRef
19.
Gulati A, Sinha A, Sreenivas V, Math A, Hari P, Bagga A (2011) Daily corticosteroids reduce infection-associated relapses in frequently relapsing nephrotic syndrome: a randomized controlled trial. Clin J Am Soc Nephrol 6(1):63–69PubMedCrossRef
20.
Allison AC, Eugui EM (2000) Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 47(2–3):85–118PubMedCrossRef
21.
Morath C, Schwenger V, Beimler J, Mehrabi A, Schmidt J, Zeier M, Muranyi W (2006) Antifibrotic actions of mycophenolic acid. Clin Transplant 20(Suppl 17):25–29PubMedCrossRef
22.
Haffner D, Fischer DC (2009) Nephrotic syndrome and rituximab: facts and perspectives. Pediatr Nephrol 24(8):1433–1438PubMedCrossRef
Metadata
Title
Outcome of severe steroid-dependent nephrotic syndrome treated with mycophenolate mofetil
Authors
Sushmita Banerjee
Amitava Pahari
Jayati Sengupta
Saroj K. Patnaik
Publication date
01-01-2013
Publisher
Springer-Verlag
Published in
Pediatric Nephrology / Issue 1/2013
Print ISSN: 0931-041X
Electronic ISSN: 1432-198X
DOI
https://doi.org/10.1007/s00467-012-2278-6

Other articles of this Issue 1/2013

Pediatric Nephrology 1/2013 Go to the issue

Brief Report

Periodic fever, aphthous stomatitis, pharyngitis, and adenitis (PFAPA) syndrome and IgA nephropathy

Educational Review

Cystic kidney diseases: many ways to form a cyst

Original Article

Renal function and injury in infants and young children with congenital heart disease

Original Article

The association of adult kidney size with childhood vesicoureteral reflux

Review

Genetics of pediatric renal tumors

Brief Report

Neonatal onset atypical hemolytic uremic syndrome successfully treated with eculizumab